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Aim: To examine the relative cost-effectiveness of predictive genetic tests for familial 
breast and ovarian cancer provided by Genetic Services of Western Australia.  
 
Methods: The relative cost-effectiveness was assessed using a decision analytic 
model.  
 
Results: The cost and outcomes of genetic testing was compared in first-degree 
relatives of known BRCA1/2 mutation-carriers who have a 50% risk of carrying the 
mutated gene (intervention group) to individuals with the same a priori risk but who 
do not undergo a genetic test (control subjects).  
 
Since genetic testing enables the restriction of intensive surveillance to individuals 
with an identified BRCA1/2 gene mutation, net savings in the period observed (age 
25-70) were $980-$1008 per woman in the ovarian intervention group and $1681-
$1795 per woman in the breast intervention group, and delayed the onset of breast 
cancer (6mths BRCA1, 3mths BRCA2).  
 
Compared to control subjects undergoing population surveillance, it was estimated the 
onset of breast cancer could be delayed at a total net cost of $3055 (5.1yrs) to $3389 
(3.2yrs) for women in the breast intervention group with BRCA1/2 mutations. Since 
population surveillance is not currently recommended for ovarian cancer, control 
subjects undergoing no surveillance were compared with the intervention group. The 
onset of ovarian cancer was delayed at a net cost of $1630 (3.5yrs) to $2509 
(1.2years) for women with BRCA1/2 mutations.  
 
Conclusions: Testing allows targeted high-level surveillance for gene mutation 
carriers, which ensures the cost-effective use of resources and reduces cancer-related 
morbidity if clinical recommendations for intervention are adopted.  
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Inherited predisposition to cancer is thought to account for 5-10% of all cancer 
incidence1. Advances in genetic testing technology have many promising applications 
in health including improved diagnosis of disease and the earlier detection of genetic 
predisposition to adult-onset conditions, such as familial cancer. This will have 
important implications for resource allocation given the capacity to compare costs 
with associated benefits. Economic evaluation helps determine the relative value of 
new technology and enables better planning for the provision of future cancer genetic 
services.  
 
In order to understand the relative cost-effectiveness of genetic testing the prevalence 
and penetrance of the gene mutation must be considered as well as the uptake and 
efficacy of available interventions to prevent or detect cancer early2. Reported 
benefits resulting from increased surveillance in women with a mutated BRCA gene 
have included earlier detection of breast cancer and an expected mortality reduction in 
women less than 50 years of age3,4. There is also evidence that prophylactic 
intervention, such as bilateral mastectomy, has been associated with a reduction in the 
incidence of breast cancer of at least 90%5. Though there is evidence to suggest 
oophrectomy reduces risk of breast cancer, it is not within the scope of this study.  
 
The absence of reliable surveillance methods for the early detection of ovarian cancer, 
and the poor prognosis following symptomatic presentation, have prompted many 
oncologists to recommend bilateral prophylactic salpingo-oophorectomy after 
childbearing6,7. Furthermore, studies have validated the prophylactic role of surgical 
intervention and provided a convincing rationale for genetic testing in women with a 
strong family history8,9.  
 
This study aimed to evaluate the relative costs and outcomes of genetic testing for 
familial breast and ovarian cancer through Genetic Services of Western Australia 
(GSWA). The investigation included familial breast and ovarian cancers suitable for 
predictive DNA based testing on the basis of inherited BRCA 1/2 mutations. The 
theoretical cohorts simulated asymptomatic first-degree relatives of individuals with a 
known BRCA1/2 mutation, who had a 50% chance of inheriting the cancer-
predisposing gene mutation.  
 
Since reliable age and gene-specific cancer mortality data were not available at the 
time of modelling for relevant population subgroups, the impact of genetic testing and 
increased surveillance on mortality was not explored in this study. Instead the study 
focus was confined to the impact of genetic testing and increased surveillance on 
reduced cancer morbidity and, accordingly ‘cancer-free years’ was the most 





Economic decision modelling software (TreeAge Data™ version 4.0) was used to 
develop a decision-analysis model, which mimicked the course of testing and 
treatment for women entering the Familial Cancer Program at GSWA. The attendance 
of women at high-risk of inherited breast or ovarian cancer in the program was 
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adequate to warrant this study. Previous studies from which much of the data is 
derived also indicated women in this risk group merited further study.  
 
Internet based searches were conducted using PubMed, Medline and Ovid on the cost-
effectiveness of genetic testing, cancer surveillance and surgical intervention to 
reduce cancer morbidity.  
 
Markov models were used to predict the age of breast and ovarian cancer onset and 
costs of surveillance for carriers of a mutated BRCA1/2 cancer gene compared with 
non-mutation carriers and control subjects.  
 
Each Markov cycle represented one year. The age and penetrance (or likelihood a 
person will develop cancer) relating to each cycle governed what proportion of 
women stayed in the ‘well’ state or shifted into the ‘cancer’ state. See Figure 1. 
 
Figure 1: Predictive genetic testing decision model for persons at high risk of 
familial breast cancer 
 
 
Surveillance strategies modelled in this study (See Table 2) were based on the 
National Health and Medical Research Council (NHMRC) clinical practice guidelines 
for the detection and treatment of familial cancer10,11 and corroborated by Western 
Australian (WA) surgeons and oncologists working in the area. Accordingly, the 
models cover the period from age 25 to 70.  
 
All women in the intervention group had predictive genetic testing to determine their 
mutation status. Inherited cancer segregates as an autosomal dominant trait, thus the 
offspring of a BRCA1/2 gene mutation carrier have a 1 in 2 chance of inheriting their 
cancer-predisposing mutation. Hence, half the women in the intervention group were 
deemed to be mutation positive and underwent intensive surveillance and prophylaxis 
as recommended. The other half were identified as mutation negative and only had 
population surveillance.  
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Control Groups  
 
Despite their high-risk family history, since control subjects did not undergo 
predictive genetic testing, their mutation status was unknown.  
 
Women may or may not have increased their surveillance based on family history 
alone (perceived breast or ovarian cancer risk) so dichotomous scenarios were 
reviewed corresponding to surveillance extremes. For example, the intervention group 
(known mutation status) was compared with control subjects (unknown mutation 
status) having either intensive surveillance and prophylaxis, or population 
surveillance. 
 
As a baseline for comparison we examined two scenarios corresponding to each 
extreme. The intervention group was first compared to control subjects (unknown 
mutation status) who adhered to clinical recommendations for increased surveillance 
based on their family history alone (control group 1). The intervention group was then 
compared with control subjects who have population or no surveillance, despite their 
high-risk family history (control group 2). The actual surveillance behaviour of 
control subjects was expected to be a mid-point between population surveillance or 




All costs are provided in Australian dollars and standardised to 2001-2002 prices 
using health index deflators12. Future costs were discounted at a rate of 5% per 
annum. Counselling, genetic testing, surveillance, surgery and treatment costs were 
based on patterns of care in WA and are consistent with NHMRC clinical practice 
guidelines for familial cancer13. Lifetime cancer treatment costs were taken from the 
Australian Institute of Health and Welfare14. Mean ages for surgery and cancer 
diagnosis were used to estimate years of discounting15, , ,16 17 18.  
 
Counselling costs were estimated in accord with GSWA and based on the average 
session time of Familial Cancer Program patients. Hourly costs were assigned based 
on staff and office requirements. Since diagnostic tests are required to confirm an 
index case before cascade testing is possible, a diagnostic cost component was also 
included.  
 
Genetic testing costs were provided by the Molecular Genetic Laboratory, Princess 
Margaret Hospital. Cancer prevention and prophylaxis costs were provided by costing 
centres in Perth’s major teaching hospitals based on a breakdown (pathology, medical, 
nursing, allied health and other) of surgical procedures in 2001-2002 and averaged to 
provide an estimate. Though capital expenditure was not assessed, a review of total 
WA health expenditure in 1999-2000 indicates this component would be less than 
5%19.  
 
Indirect costs were not included.  
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Outcomes on the effectiveness of cancer screening and interventions on cancer 
incidence in these high risk individuals were derived from the published literature. 
Age-related ‘population risk’ of breast cancer represented national rates in 200020. To 
enable comparisons between the simulated cohorts breast and ovarian cancer were 
examined separately and the risks of developing the two cancers were assumed to be 
independent.  
 
Cumulative age-related cancer incidence in mutation carriers, with and without the 
recommended clinical intervention, were gathered from previous studies and factored 
for attrition, and hence took account of all-cause mortality. The age-specific ‘inherited 
risk’ of breast cancer in BRCA1/2 mutation-carriers was based on 65% or 45% 
penetrance respectively by age 70 consistent with studies by Antoniou et al21. The 
age-specific ‘inherited risk’ of ovarian cancer in mutation-carriers was based on 39% 
or 11% penetrance for BRCA1/2 respectively by age 70, as previously reported22.  
 
The simulated population represented offspring of known mutation-carriers (at 50% 
risk of inheriting the gene mutation) and assumed full compliance with NHMRC 
clinical recommendations for intervention23.  
 
Interventions modelled on behalf of population or intensive surveillance and 
prophylaxis are listed in Table 1. For each intervention the optimal age, required 
frequency of an event and the non-discounted cost is reported. 
 
Based on trends in WA, it was assumed that around 30%24 of the breast intervention 
group would elect prophylactic bilateral mastectomy at a mean age of 38 years, with a 
lifetime reduction in breast cancer risk of 90%25,26 since many women elect 
surveillance but no surgery, this option was examined within the model.  
Mammographic screening of women between 50-69 years has been shown to reduce 
their lifetime risk of breast cancer by 35%27. Previous studies indicated that the 
younger age of cancer diagnosis in women with BRCA mutations justified screening 
from an earlier age28, , , ,29 30 31 32. On this basis it was presumed that mutation carriers 
aged 35 to 49 would also reduce their lifetime risk of breast cancer by 35% though 
mammographic screening and clinical breast examination.  
 
The available screening measures for ovarian cancer, such as transvaginal ultrasound 
and serum CA-125, have limited sensitivity and specificity and may not reduce 
ovarian cancer mortality33. For this reason it was assumed that all women in the 
intervention group would undergo the recommended prophylactic salpingo-
oophorectomy at age 40 and achieve a lifetime reduction in ovarian cancer risk of 
96% as previously reported34,35. Sensitivity analysis was used to test the effects of 
varying these outcomes. 
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Costs associated with genetic testing, surveillance, prophylaxis and cancer treatment 
are listed in Table 1. Estimated total surveillance costs are listed in Table 2.  
 
Table 1: Intervention costs at 2001-2002 prices 
 
Intervention Age of intervention 
(yrs)
Frequency of event Cost per event 
(undiscounted)
    
Genetic counselling + test, carrier once only $1,012 
  
Ovarian Cancer Intensive Surveillance & Prophylaxis  
Transvaginal ultrasound 35*-40 12mths $129 
CA125 35-40 12mths $24 
Prophylactic salpingo-oophorectomy 40 once only $7,216 
  
Breast Cancer Intensive Surveillance & Prophylaxis  
Clinical breast examination 25-37 4mths $65
Mammogram  35*-37 12mths $163
Prophylactic bilateral mastectomy 38 once only $11,547
CT chest scan post surgery 39 once only $175
Clinical ex. of chest wall and lymph nodes 39-70 6mths $65
  
Breast Cancer Intensive Surveillance only  
Clinical breast examination 25-70 4mths $65
Mammogram  35*-70 12mths $163
  
Population Surveillance (breast cancer only)  
Mammogram 50-69 24mths       $163 
  
Ovarian cancer treatment (life)  once only   $19,735 
Breast cancer treatment (life) once only   $11,616 
*Or 5yrs before youngest affected family member 
 
Table 2: Total surveillance costs 
 
Intervention No Discount 5% Discount
Breast Cancer   
Intensive surveillance and prophylaxis $18,906 $9,785
Intensive surveillance only $14,838 $6,493
Population surveillance $1,630 $315
 
Ovarian Cancer 
Intensive surveillance and prophylaxis $7,981 $3,381
Population surveillance n/a n/a
 
Results of the cost-effectiveness analysis of genetic testing for familial breast cancer 
are shown in Figure 2. The intervention group was compared to control subjects for 
the period modelled (age 25-70). Costs incurred in the future have been discounted. 
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Intervention effectiveness was measured by the number of years that the onset of 
cancer is delayed. 
 






























BRCA1&2: $1593 (44.7CFY) 
Cost (outcome) 
BRCA1 $2545 (38.5 CFY) 
BRCA2 $1978 (41.0 CFY) 
Overall cost (outcome) 
BRCA1 $5600 (43.6CFY) 
BRCA2 $5367 (44.2 CFY) 
For each woman that undertook genetic testing for breast cancer: 
o Compared to Control Group 1, BRCA1 intervention provided total net savings of $1795 and delayed the onset of breast cancer by 6 months; 
BRCA2 intervention provided total net savings of $1681 and the cancer onset was delayed by 3 months;  
o Compared to Control Group 2, BRCA1 intervention incurred a $3055 total net cost but delayed the onset of breast cancer by 5.1 years ($601 
per cancer-free year gained); BRCA2 intervention incurred $3389 total net cost for a gain of 3.2 cancer-free years, ($1070 per cancer-free 
year gained). 
Cost (outcome) 
BRCA1 $7395 (43.0 CFY) 
BRCA2 $7048 (43.9 CFY) 
Population Surveillance 
(Control 2) 
Mutation Status Unknown  
 







BRCA1 $9608 (42.4 CFY) 
BRCA2 $9141 (43.7 CFY) 
 
Compared to control subjects undergoing high-level surveillance since their mutation 
status is unknown, targeted BRCA1 intervention provided total net savings of $1795 
per woman and delayed the onset of breast cancer by 6 months. Likewise, BRCA2 
intervention provided total net savings of $1681 and delayed cancer by 3 months. 
 
Compared to control subjects having population surveillance, BRCA1 intervention 
incurred a total net cost of $3055 per woman but improved her outcome by 5.1 
cancer-free years which is $601 per cancer-free year gained. Similarly, BRCA2 
intervention delayed the onset of breast cancer by 3.2 years, at a total net cost of 
$3389 or, $1070 for each cancer-free year gained. 
 
The cost-effectiveness analysis of genetic testing for familial ovarian cancer is shown 
in Figure 3.  
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Though the number of cancer-free years was the same in both the intervention group 
and control subjects undergoing high-level surveillance, targeted surveillance in the 
intervention group provided total net savings of $980-$1008 per woman for BRCA1 




BRCA1 $4795 (45.7 CFY) 
BRCA2 $4843 (46.0 CFY) 
Control Group 2 
Cost (outcome) 
BRCA1 $1298 (44.7 CFY) 
BRCA2 $353 (44.7 CFY) 
Intervention Group 
Cost (outcome) 
BRCA1 $2928 (45.8 CFY) 
BRCA2 $2862 (45.9CFY) 
Control Group 1 
Cost (outcome) 
BRCA1 $3908 (45.8 CFY) 
BRCA2 $3870 (45.9 CFY) 
Mutation Negative 
Cost (outcome) 
BRCA1&2 $881 (45.9 CFY) 
Thus each woman that undertook genetic testing for ovarian cancer: 
o Compared to Control Group 1, provided total net savings of $ 980-$1,008 for BRCA1 and 2 intervention respectively with no 
change in effectiveness;  
o Compared to Control Group 2, BRCA1 i t rvention incurred a $1630 total net cost but delayed the onset of ovarian cancer 
by 3.5 years ($477 per cancer-free year gained); BRCA2 intervention incurred $2509 total net cost for a gain of 1.2 cancer-
free years, ($2150 per cancer-free year gained). 
Compared to control subjects undergoing no surveillance, BRCA1 intervention 
incurred a $1630 total net cost but delayed the onset of ovarian cancer by 3.5 years 
($477 per cancer-free year gained); BRCA2 intervention incurred $2509 total net cost 




One-way sensitivity analysis was utilised to check the stability of the outcome given 
uncertainty in some variables, specifically the penetrance of BRCA mutations. Since 
this varied widely in the published literature36 cumulative cancer incidence by age 70 
was explored using reported confidence intervals37. The results shown in Table 3 
indicated that a higher level of penetrance would provide the intervention group with 
increased effectiveness (cancer-free years gained) for a lower net cost or greater net 
savings compared to no genetic testing. 
 
Table 3: Impact of adjusted mutation penetrance on cost-effectiveness 
 
Cancer type Penetrance Cumulative 
incidence 
Net Saving1 Net Cost2
Breast:       BRCA1 Low 44% $1687 (3mths) $3581 (3.2yrs) 
 High 78% $1900 (7mths) $2656 (6.6yrs) 
       BRCA2  Low 31% $1642 (2mths) $3865 (2.3yrs) 
 High 56% $1719 (4mths) $3403 (3.9yrs) 
     
Ovarian:   BRCA1 Low 18% $1011 (0mths) $2289 (1.8yrs) 
  High 54% $1002 (1mth) $1056 (5.0yrs) 
  BRCA2 Low 2.4% $993 (1mth) $2765 (6mths) 
 High 19% $1011 (0mths) $2265 (1.8yrs) 
 
                                                 
1 Compared to control subjects having intensive surveillance 
2 Compared to control subjects having population or no surveillance 
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The estimated number of women that elect prophylactic bilateral mastectomy to 
prevent breast cancer in Western Australia (30%) is low compared to the uptake in 
The Netherlands (51%)38. The impact on cost-effectiveness of higher uptake was 
examined in the breast models (see Table 4). A greater uptake of prophylactic 
mastectomy in high-risk women compared to surveillance alone was found to increase 
the cost-effectiveness of genetic testing.  
 
Table 4: Impact of prophylactic bilateral mastectomy uptake on cost-
effectiveness
 
 Prophylactic uptake Net Saving1 Net Cost2
BRCA1 0% $2125 (1mth) $2725 (4.6yrs) 
 30% $1795 (6mths) $3055 (5.1yrs) 
 50% $1574 (9mths) $3276 (5.4yrs) 
    
BRCA2 0% $2081 (0mths) $3179 (2.9yrs) 
 30% $1691 (3mths) $3569 (3.2yrs) 
 50% $1432 (5mths) $3828 (3.4yrs) 
 
The impact of various discount rates (0, 3%, 5% and 7%) on the net cost or saving in 
the breast (BRCA1) intervention group was examined in Table 5.  
 
Table 5: Discount rate effect on net cost or savings in the breast-BRCA1 
intervention group 
 
Discount rate Net Saving1 Net Cost2
No discount $5028 $5012 
Discount 3% $2687 $3550 
Discount 5% $1795 $3055 
Discount 7% $1232 $2724 
 
The application of a 3% discount rate instead of the 5% rate utilised would increase 
per person net savings by $892 or, increase the per person net cost by $495 for the 
period observed, depending on the surveillance undertaken by control subjects. 
Findings were similar for the ovarian intervention group when the discount rate was 




Early detection and intervention strategies resulting from predictive genetic testing for 
BRCA1/2 mutations in Western Australia has been demonstrated to be a cost-
effective use of resources under a range of scenarios.   
 
Genetic testing enables the restriction of intensive surveillance to individuals with an 
identified BRCA1/2 gene mutation, leading to large net savings for the period 
observed (age 25-70). Compared with control subjects undergoing intensive 
surveillance and prophylaxis, the ovarian intervention group provided total net 
savings of $980-$1008 per woman. The breast intervention group provided total net 
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savings of $1681-$1795 per woman and delayed the onset of breast cancer (6mths 
BRCA1, 3mths BRCA2).   
 
Compared to control subjects undergoing only population surveillance, it was 
predicted the onset of cancer could be delayed in the genetic testing intervention 
group. For example, breast cancer could be delayed at a total net cost of $3055 
(5.1yrs) to $3389 (3.2yrs) for women with identified BRCA1/2 mutations. This is a 
cost of $601 or $1070 per cancer-free year gained. Since population surveillance is 
not currently recommended for ovarian cancer, control subjects undergoing no 
surveillance were compared with women in the intervention group who were expected 
to delay the onset of ovarian cancer at a net cost of $1630 (3.5yrs) to $2509 (1.2years) 
for women with BRCA1/2 mutations. This is a cost of $477 or $2150 per cancer-free 
year gained.  
 
These findings are consistent with a study by Tengs and Berry39 which found BRCA 
testing of high-risk women to be cost-effective, with estimated savings of $3400- 
$4700 per quality-adjusted life-year gained in a 30-year-old woman. Grann et al40 
also found genetic screening women to be cost-effective in Ashkenazi Jewish, but 
only if known mutation-carriers underwent the recommended prophylaxis. In the 
current study, genetic testing for BRCA mutations was found to be cost-effective even 
if women elected increased surveillance but declined surgery.  
 
In addition to the reduction of cancer morbidity, benefits of predictive genetic testing 
include reduced anxiety from an unknown genetic background and the ability to make 
proactive decisions regarding medical and lifestyle options to prevent or minimise the 
risk of breast or ovarian cancer. The confirmation of risk status may also have 
important implications for family planning.  
 
Although intangible costs and benefits were not explored in this study, aspects such as 
the psychological impact of extreme surgery, particularly bilateral mastectomy, on 
body image and sexuality warrants concern. However, a study by Hatcher et al found 
bilateral prophylactic mastectomy in women with high familial risk reduced 
psychological morbidity and anxiety and did not have a detrimental impact on 
women's body image or sexual functioning. They noted that women who chose such 
surgery had undergone more investigative tests than women who declined and had a 
higher, often inaccurate, perception of their risk of developing breast cancer41. Given 
the complexity of genetic risk communication this finding was not unexpected since 
confirmation as a BRCA mutation-carrier provides no certainty when, or if, cancer 
will occur in an individual, nor can a negative BRCA mutation result guarantee an 
individual will not develop cancer.  
 
For clarity and comparison purposes the models were cancer and mutation specific. 
This represented a limitation of the study since some women may develop both breast 
and ovarian cancer and rarely carry both BRCA1 and BRCA2 mutations. We also 
assumed high-level patient compliance with clinical recommendations for 
intervention since the cost-effectiveness of genetic testing depends on compliance.  
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The value of regular surveillance in women with a genetic or familial predisposition 
to breast cancer is uncertain42 although many studies have indicated a potential 
benefit for young women with a family history of cancer43, , ,44 45 46. Other research 
suggested screening may be less effective since women with these mutations were 
more likely to develop cancer before menopause when breast tissue was dense, 
making it difficult to detect tumours on a mammogram47. Additionally the rate of 
growth of breast cancer is often faster in younger women, which can also decrease the 
effectiveness of screening at regular intervals48.  
 
Findings by Kreige et al49 indicated magnetic resonance imaging was more sensitive 
than mammography for detecting beast cancers in women at increased risk because of 
inherited susceptibility. It is hoped that future research will provide clarity on the 
efficacy of intensive breast or ovarian cancer surveillance in known mutation-carriers.  
 
The success of a genetic screening program however is dependent largely upon the 
compliance of clients with clinical recommendations for surveillance and the 
disclosure of mutation status by the proband to genetic relatives. In addition, the 
uptake of prophylactic surgery varies greatly between nations. In the Netherlands 51% 
of asymptomatic mutation carriers opted for bilateral mastectomy and 64% for 
oophorectomy50 while the proportion of mutation-carriers that elect prophylaxis in 
Western Australia is around 30%51.  
 
According to Grann et al52 screening for BRCA mutations in the Ashkenazi Jewish 
population is only cost-effective if all women who tested positive underwent 
prophylactic surgery. However, this approach is complicated by prophylactic 
mastectomy not being totally protective, since breast cancer has been documented in 
women following prophylactic surgery53,54 and evidence that genetic information may 
even reduce motivation to change health behaviour55. Scheuer56 found that genetic 
counselling and testing increased compliance with surveillance and led to risk-
reducing operations and diagnosis of early-stage tumours in patients with BRCA1/2 
mutations. 
 
Investigation into the uptake of prophylactic surgery in Australia, the impact of 
cultural differences and support in the medical sector for such interventions may 
provide insight into levels of patient compliance with clinical recommendations and 
help shape future intervention protocols.  
 
Early detection and intervention through predictive genetic testing for BRCA 
mutations in Western Australia has been demonstrated to be a relatively cost-effective 
use of resources under a range of scenarios, though further studies are needed to 
verify the results of long-term gains and, or costs from genetic testing. Additional 
research into compliance with clinical recommendations for surveillance, the 
disclosure of risk information to relatives and the degree of community support for 
such programs is required, since the cost-effectiveness of genetic testing will depend 
on the value of this information to patients and society. 
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